```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1805sxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced
 NEWS  4  APR 07  STN is raising the limits on saved answers
 NEWS  5  APR 24  CA/CAplus now has more comprehensive patent assignee
                  information
 NEWS  6  APR 26  USPATFULL and USPAT2 enhanced with patent
                  assignment/reassignment information
 NEWS  7  APR 28  CAS patent authority coverage expanded
 NEWS  8  APR 28  ENCOMPLIT/ENCOMPLIT2 search fields enhanced
 NEWS  9  APR 28  Limits doubled for structure searching in CAS
                  REGISTRY
 NEWS 10  MAY 08  STN Express, Version 8.4, now available
 NEWS 11  MAY 11  STN on the Web enhanced
 NEWS 12  MAY 11  BEILSTEIN substance information now available on
                  STN Easy
 NEWS 13  MAY 14  DGENE, PCTGEN and USGENE enhanced with increased
                  limits for exact sequence match searches and
                  introduction of free HIT display format
 NEWS 14  MAY 15  INPADOCDB and INPAFAMDB enhanced with Chinese legal
                  status data
 NEWS 15  MAY 28  CAS databases on STN enhanced with NANO super role in
                  records back to 1992
 NEWS 16  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:31:16 ON 15 JUN 2009
```

```
=> file medline caplus embase biotechno biosis scisearch
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.22       0.22

FILE 'MEDLINE' ENTERED AT 11:31:57 ON 15 JUN 2009

FILE 'CAPLUS' ENTERED AT 11:31:57 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:31:57 ON 15 JUN 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 11:31:57 ON 15 JUN 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:31:57 ON 15 JUN 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 11:31:57 ON 15 JUN 2009
Copyright (c) 2009 The Thomson Corporation

=> s muc1 or muc-1
L1       13966 MUC1 OR MUC-1

=> s l1 and antisense
L2         126 L1 AND ANTISENSE

=> s l1 and siRNA
L3         115 L1 AND SIRNA

=> s l2 and fas
L4           2 L2 AND FAS

=> s l3 and fas
L5          44 L3 AND FAS

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6             4 DUP REM L5 (40 DUPLICATES REMOVED)

=> dup rem l4
PROCESSING COMPLETED FOR L4
L7             2 DUP REM L4 (0 DUPLICATES REMOVED)

=> d 1-4 l6 ab

L6   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN  DUPLICATE 1
AB   The present invention relates to MHC-peptide complexes and uses thereof in
     the diagnosis of, treatment of or vaccination against a disease in an
     individual.  More specifically the invention discloses MHC complexes
     comprising Mycobacterium tuberculosis antigenic peptides and uses there
     of.  [This abstract record is one of 51 records for this document
     necessitated by the large number of index entries required to fully index the
     document and publication system constraints].

L6   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
AB   The present invention describes novel methods to generate MHC or HLA
     multimers and methods to improve existing and new MHC multimers.  The
```

invention also describes improved methods for the use of MHC multimers in anal. of T-cells in samples 5 including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumor and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable target cells or isolation of specific T-cells capable of regulation of other immune cells.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AB Novel compds. carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compds. possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC mols. are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool, e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compns. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AB The presently disclosed subject matter provides modified cell-derived exosomes substantially lacking one or more immunosuppressive polypeptides. The presently-disclosed subject matter further provides methods of producing the modified exosomes and methods of using the modified exosomes for treating cancers.

=> d l5 ti 1-44

L5 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN

TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN

TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis

L5 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI MHC multimers and conjugates for use in diagnosis, prognosis and therapy of cancer, infection, immune and autoimmune disease

L5 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI MHC-peptide complexes and MHC multimers for diagnosis, prognosis and therapy of cancer, allergy, immune or autoimmune disease, transplant rejection, infection and vaccine development

L5 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2009 ACS on STN
TI Tumor antigen-containing exosomes modified with polynucleotides to inhibit expression of immunosuppressive polypeptides for use as vaccine against cancer

=> d 1-2 l7

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:976940 CAPLUS
DN 143:260343
TI MUC1 antagonist enhancement of death receptor ligand-induced apoptosis
IN Kufe, Donald W.; Kharbanda, Surender
PA Ilex Products, Inc., USA; Dana-Farber Cancer Institute, Inc.
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082458	A1	20050909	WO 2005-US5508	20050222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2556729	A1	20050909	CA 2005-2556729	20050222
	EP 1718367	A1	20061108	EP 2005-713897	20050222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007523214	T	20070816	JP 2007-500916	20050222
	US 20070202134	A1	20070830	US 2007-598295	20070405
PRAI	US 2004-547010P	P	20040223		
	WO 2005-US5508	W	20050222		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:934231 CAPLUS
DN 141:375492
TI Identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis
IN Yehiely, Fruma; Deiss, Louis; Einat, Paz
PA USA
SO U.S. Pat. Appl. Publ., 32 pp., Cont.-in-part of U.S. Ser. No. 499,553, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040219569	A1	20041104	US 2003-704112	20031107
	WO 9821366	A1	19980522	WO 1997-US20989	19971112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6057111	A	20000502	US 1999-284782	19990706
	US 20050272056	A1	20051208	US 2005-31356	20050107
	US 20070042418	A1	20070222	US 2006-586021	20061024
PRAI	WO 1997-US20989	W	19971112		
	US 1999-284782	A2	19990706		
	US 2000-499553	B2	20000207		
	US 1996-30549P	P	19961113		
	US 2003-704112	A2	20031107		

=> d kwic l7 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
TI Identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis
ST antisense RNA selection subtractive hybridization essential gene cloning; Fas dependent apoptosis regulating gene cloning
IT Genetic methods
(AHM (achilles heel method), in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Adenosine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A3, inhibitors of, in control of apoptosis and treatment of auto-immune disease; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Organelle
(COP9 signalosome, inhibitors of, in control of apoptosis; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in

Fas pathway of apoptosis)

IT Apoptosis
(Fas regulation of; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GABP (GA-binding protein), inhibitors of, in control of apoptosis; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Genetic methods
(GSE (genetic suppressor element), in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1, inhibitors of, in control of apoptosis and treatment of auto-immune disease; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Retinoic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RAR-γ, inhibitors of, in control of apoptosis and treatment of auto-immune disease; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Genetic methods
(RKTKO (random homozygous knock out), in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Genetic methods
(TKO (tech. knock out), in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Tumor necrosis factor receptor-associated factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TRAF6; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT cDNA library
(antisense; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Genetic methods
(differential display, in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT DNA microarray technology
(gene expression microarrays, in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT HeLa cell
(identification of essential genes in; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

IT Cell proliferation
Gene expression profiles, animal
Phenotypes
(identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Antisense RNA
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT DNA sequence analysis
(in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(parathyroid hormone-cross-reacting; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Fas antigen
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulation of apoptosis mediated by; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Genetic methods
(representational differential anal. (RDA), in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Genetic methods
(serial anal. of gene expression (SAGE), in identification of essential genes; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Nucleic acid hybridization
(subtractive; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT Autoimmune disease
(treatment of; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT 9000-94-6, Antithrombin III
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(III, inhibitors of, in control of apoptosis and treatment of auto-immune disease; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT 163200-99-5, GenBank T62060 391808-82-5, GenBank AA056626 391812-72-9, GenBank AA088258 391987-93-2, GenBank AA456295 392001-49-9, GenBank AA488073 392004-88-5, GenBank AA489699 392008-90-1, GenBank AA496438 392045-32-8, GenBank AA863086
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(identification of genes essential for cellular function using

antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT 57-96-5 66-76-2, Dicumarol 616-91-1, N-Acetyl cysteine 120615-25-0, CKI 7
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in control of apoptosis and treatment of auto-immune disease; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)
IT 52660-18-1, Casein kinase 106096-93-9, Basic fibroblast growth factor 475489-73-7, Calmodulin-dependent protein kinase II
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors of, in control of apoptosis and treatment of auto-immune disease; identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in Fas pathway of apoptosis)

=> d his

(FILE 'HOME' ENTERED AT 11:31:16 ON 15 JUN 2009)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOTECHNO, BIOSIS, SCISEARCH' ENTERED AT 11:31:57 ON 15 JUN 2009
L1 13966 S MUC1 OR MUC-1
L2 126 S L1 AND ANTISENSE
L3 115 S L1 AND SIRNA
L4 2 S L2 AND FAS
L5 44 S L3 AND FAS
L6 4 DUP REM L5 (40 DUPLICATES REMOVED)
L7 2 DUP REM L4 (0 DUPLICATES REMOVED)

=> s l3 and cancer
L8 87 L3 AND CANCER

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9 37 DUP REM L8 (50 DUPLICATES REMOVED)

=> s l9 and apoptosis
L10 9 L9 AND APOPTOSIS

=> d 1-9 ab

L10 ANSWER 1 OF 9 MEDLINE on STN
AB INTRODUCTION: MUC1 is an oncoprotein whose overexpression correlates with aggressiveness of tumors and poor survival of cancer patients. Many of the oncogenic effects of MUC1 are believed to occur through interaction of its cytoplasmic tail with signaling molecules. As expected for a protein with oncogenic functions, MUC1 is linked to regulation of proliferation, apoptosis , invasion, and transcription. METHODS: To clarify the role of MUC1 in cancer, we transfected two breast cancer cell lines (MDA-MB-468 and BT-20) with small interfering (si)RNA directed against MUC1 and analyzed transcriptional responses and oncogenic events (proliferation, apoptosis and invasion). RESULTS: Transcription of several genes was altered after transfection of MUC1 siRNA, including decreased MAP2K1 (MEK1), JUN, PDGFA, CDC25A, VEGF and ITGAV (integrin alphav), and increased TNF, RAF1, and MMP2. Additional changes were seen at the protein level, such as increased expression of c-Myc, heightened phosphorylation of AKT, and

decreased activation of MEK1/2 and ERK1/2. These were correlated with cellular events, as MUC1 siRNA in the MDA-MB-468 line decreased proliferation and invasion, and increased stress-induced apoptosis. Intriguingly, BT-20 cells displayed similar levels of apoptosis regardless of siRNA, and actually increased proliferation after MUC1 siRNA. CONCLUSION: These results further the growing knowledge of the role of MUC1 in transcription, and suggest that the regulation of MUC1 in breast cancer may be more complex than previously appreciated. The differences between these two cell lines emphasize the importance of understanding the context of cell-specific signaling events when analyzing the oncogenic functions of MUC1, and caution against generalizing the results of individual cell lines without adequate confirmation in intact biological systems.

L10 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of. [This abstract record is one of 51 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

L10 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention describes novel methods to generate MHC or HLA multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in anal. of T-cells in samples 5 including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumor and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable target cells or isolation of specific T-cells capable of regulation of other immune cells.

L10 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AB Novel compds. carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compds. possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC mols. are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool, e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compns. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

L10 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AB The invention provides methods of identifying and making compds. that inhibit the interaction between MUC1 and galectin-3. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of galectin-3 by a cell. Such compds. can be useful for directly promoting apoptosis of MUC1-expressing cancer cells, for enhancing the efficacy of genotoxic chemotherapeutic agents against such cancer cells, and as anticancer prophylactic agents.

L10 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention discloses a method of using compds., which have HDM2

protein antagonist activity, to treat or prevent cancer, other diseases caused by abnormal cell proliferation, diseases associated with HDM2, or diseases caused by inadequate P53 activity.

L10 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

AB The invention provides methods for treating cancer and diagnosing cancer with zinc transporter LIV-1 modulators such as antibodies, siRNAs or shRNAs. In particular, the present invention provides compns. and methods for treating, diagnosing and detecting cancers associated with LIV-1 overexpression. LIV-1 was over-expressed in ER-pos., ER-neg. and metastatic breast tumor and up-regulated in other tumors. LIV-1 specific siRNAs knockdowned LIV-1 protein and inhibited tumor cell growth. Caspase activation induced by LIV-1 knockdown suggested that observed cell death may be mediated by apoptosis. LIV-1 knockdown reduced cyclin D1 level in tumor cells. LIV-1 specific antibodies and siRNAs reduced cytoplasmic zinc levels. Treatment with anti-LIV-1 antibody decreased cyclin D1 levels after 6 h. The sequences of LIV-1 epitopes are provided. Th protein and cDNA sequences of human zinc transporter LIV-1 are also provided.

L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

AB Introduction MUC1 is an oncoprotein whose overexpression correlates with aggressiveness of tumors and poor survival of cancer patients. Many of the oncogenic effects of MUC1 are believed to occur through interaction of its cytoplasmic tail with signaling mols. As expected for a protein with oncogenic functions, MUC1 is linked to regulation of proliferation, apoptosis , invasion, and transcription. Methods To clarify the role of MUC1 in cancer, we transfected two breast cancer cell lines (MDA-MB-468 and BT-20) with small interfering (si)RNA directed against MUC1 and analyzed transcriptional responses and oncogenic events (proliferation, apoptosis and invasion). Results Transcription of several genes was altered after transfection of MUC1 siRNA, including decreased MAP2K1 (MEK1), JUN, PDGFA, CDC25A, VEGF and ITGAV (integrin αv), and increased TNF, RAF1, and MMP2. Addnl. changes were seen at the protein level, such as increased expression of c-Myc, heightened phosphorylation of AKT, and decreased activation of MEK1/2 and ERK1/2. These were correlated with cellular events, as MUC1 siRNA in the MDA-MB-468 line decreased proliferation and invasion, and increased stress-induced apoptosis. Intriguingly, BT-20 cells displayed similar levels of apoptosis regardless of siRNA, and actually increased proliferation after MUC1 siRNA. Conclusion These results further the growing knowledge of the role of MUC1 in transcription, and suggest that the regulation of MUC1 in breast cancer may be more complex than previously appreciated. The differences between these two cell lines emphasize the importance of understanding the context of cell-specific signaling events when analyzing the oncogenic functions of MUC1, and caution against generalizing the results of individual cell lines without adequate confirmation in intact biol. systems.

L10 ANSWER 9 OF 9 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN

AB The MUC1 transforming protein is overexpressed by most human carcinomas. The present studies demonstrate that the MUC1C-terminal subunit (MUC1 C-ter) localizes to mitochondria in HCT116/ MUC1 colon carcinoma cells and that heregulin stimulates mitochondrial targeting of MUC1 C-ter. We also show that MUC1 attenuates cisplatin-induced (1) release of mitochondrial apoptogenic factors, (2) activation of caspase-3, and (3) induction of apoptosis. Moreover, knockdown of MUC1 expression in

A549 lung and ZR-75-1 breast carcinoma cells by MUC1 siRNA was associated with increased sensitivity to genotoxic drugs in vitro and in vivo. These findings indicate that MUC1 attenuates the apoptotic response to DNA damage and that this oncoprotein confers resistance to genotoxic anticancer agents.

=> s l2 and apoptosis
L11 17 L2 AND APOPTOSIS

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 17 DUP REM L11 (0 DUPLICATES REMOVED)

=> d 1-17 ti

L12 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Combinations for the treatment of B-cell proliferative disorders

L12 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Identification of compounds that inhibit interaction of MUC1 and galectin-3 for treatment of cancer

L12 ANSWER 3 OF 17 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI MUC1 mediates cell survival and metastasis potential of NSCLC cells through interactions with tyrosine kinase and STAT signaling pathways.

L12 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Zinc transporter LIV-1 modulator for treatment and diagnosis of tumors

L12 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Methods and compositions for generating bioactive assemblies of increased complexity and their therapeutic and diagnostic uses

L12 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Modulation of MUC1 activity by inhibiting the interaction between MUC1 and p53 and design of anticancer agents

L12 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI MUC1 antagonist enhancement of death receptor ligand-induced apoptosis

L12 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Gene expression profiles in the diagnosis and treatment of Alzheimer's disease

L12 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Combinatorial cancer gene therapy using combinations of tumor- and/or tissue-specific promoters regulating expression of proapoptotic genes

L12 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Genes essential for the survival of eukaryotic cells in the absence of a functional Rb gene

L12 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Cancer treatment by metabolic modulations to stimulate glycogen accumulation to toxic levels

L12 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Identification of genes essential for cellular function using antisense DNA libraries and identification of genes involved in

Fas pathway of apoptosis

L12 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Monoclonal anti-MUC1 antibody PAM4 and chimeric antibodies for diagnosis and therapy of pancreatic cancer

L12 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer

L12 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Anti-CD20 antibodies and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases

L12 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Method for controlling the replication of non-replicative adenovirus using selectively replicative adenovirus in cancer gene therapy

L12 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
TI Engineering of replication selective adenoviruses with tumor-associated antigen promoter for use in cancer therapy

=> d l10 1 5 8 9

L10 ANSWER 1 OF 9 MEDLINE on STN
AN 2007027281 MEDLINE
DN PubMed ID: 16846534
TI MUC1 alters oncogenic events and transcription in human breast cancer cells.
AU Hattrup Christine L; Gendler Sandra J
CS Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.. hattrup.christine@mayo.edu
NC R01 CA64389 (United States NCI NIH HHS)
SO Breast cancer research : BCR, (2006) Vol. 8, No. 4, pp. R37.
Journal code: 100927353. E-ISSN: 1465-542X.
Report No.: NLM-PMC1779460.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA English
FS Priority Journals
EM 200701
ED Entered STN: 17 Jan 2007
Last Updated on STN: 26 Jan 2007
Entered Medline: 25 Jan 2007

L10 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:735655 CAPLUS
DN 149:70425
TI Identification of compounds that inhibit interaction of MUC1 and galectin-3 for treatment of cancer
IN Kufe, Donald W.
PA Dana-Farber Cancer Institute, Inc., USA
SO PCT Int. Appl., 88pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2008073817 A2 20080619 WO 2007-US86760 20071207
WO 2008073817 A3 20080925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2006-873847P P 20061208

L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:764088 CAPLUS
DN 145:393790
TI MUC1 alters oncogenic events and transcription in human breast cancer cells
AU Hattrup, Christine L.; Gendler, Sandra J.
CS Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, 85259, USA
SO Breast Cancer Research (2006), 8(4), No pp. given
CODEN: BRCRFS; ISSN: 1465-542X
URL: http://breast-cancer-research.com/content/pdf/bcr1515.pdf
PB BioMed Central Ltd.
DT Journal; (online computer file)
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 9 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
AN 2004:237558 SCISEARCH
GA The Genuine Article (R) Number: 779GG
TI Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
AU Kufe D (Reprint)
CS Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA (Reprint)
AU Ren J; Agata N; Chen D S; Li Y Q; Yu W H; Huang L; Raina D; Chen W; Kharbanda S
CS Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; ILEX Prod Inc, Boston, MA 02215 USA
CYA USA
SO CANCER CELL, (FEB 2004) Vol. 5, No. 2, pp. 163-175.
ISSN: 1535-6108.
PB CELL PRESS, 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA.
DT Article; Journal
LA English
REC Reference Count: 52
ED Entered STN: 19 Mar 2004
Last Updated on STN: 19 Mar 2004
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

=> d l12 6 7 13 14

L12 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:845302 CAPLUS

DN 145:263265
TI Modulation of MUC1 activity by inhibiting the interaction between MUC1 and p53 and design of anticancer agents
IN Kufe, Donald W.
PA Dana-Farber Cancer Institute, Inc., USA
SO PCT Int. Appl., 106pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006088906	A2	20060824	WO 2006-US5239	20060214
	WO 2006088906	A3	20090430		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2597627	A1	20060824	CA 2006-2597627	20060214
	EP 1853304	A2	20071114	EP 2006-735077	20060214
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008537095	T	20080911	JP 2007-555349	20060214
	US 20080286264	A1	20081120	US 2008-816402	20080502
PRAI	US 2005-652918P	P	20050215		
	US 2005-654009P	P	20050217		
	WO 2006-US5239	W	20060214		

L12 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:976940 CAPLUS
DN 143:260343
TI MUC1 antagonist enhancement of death receptor ligand-induced apoptosis
IN Kufe, Donald W.; Kharbanda, Surender
PA Ilex Products, Inc., USA; Dana-Farber Cancer Institute, Inc.
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082458	A1	20050909	WO 2005-US5508	20050222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,				

MR, NE, SN, TD, TG
CA 2556729 A1 20050909 CA 2005-2556729 20050222
EP 1718367 A1 20061108 EP 2005-713897 20050222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
JP 2007523214 T 20070816 JP 2007-500916 20050222
US 20070202134 A1 20070830 US 2007-598295 20070405
PRAI US 2004-547010P P 20040223
WO 2005-US5508 W 20050222
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:1007015 CAPLUS
DN 140:58438
TI Monoclonal anti-MUC1 antibody PAM4 and chimeric antibodies for diagnosis and therapy of pancreatic cancer
IN Gold, David V.; Goldenberg, David M.; Hansen, Hans
PA Immunomedics, Inc., USA; McCall, John Douglas
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003106497	A1	20031224	WO 2003-GB2585	20030616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489469	A1	20031224	CA 2003-2489469	20030616
AU 2003250367	A1	20031231	AU 2003-250367	20030616
US 20040057902	A1	20040325	US 2003-461878	20030616
US 7238786	B2	20070703		
EP 1521775	A1	20050413	EP 2003-760086	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507803	T	20060309	JP 2004-513328	20030616
PRAI US 2002-388313P	P	20020614		
WO 2003-GB2585	W	20030616		

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:1007014 CAPLUS
DN 140:58437
TI Multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer
IN Goldenberg, David M.; Hansen, Hans; Qu, Zhengxing
PA Immunomedics, Inc., USA; McCall, John Douglas
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003106495	A2	20031224	WO 2003-GB2593	20030616
	WO 2003106495	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489467	A1	20031224	CA 2003-2489467	20030616
	AU 2003277087	A1	20031231	AU 2003-277087	20030616
	AU 2003277087	B2	20080731		
	US 20050014207	A1	20050120	US 2003-461885	20030616
	US 7282567	B2	20071016		
	EP 1519958	A2	20050406	EP 2003-740743	20030616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003011799	A	20050510	BR 2003-11799	20030616
	CN 1675245	A	20050928	CN 2003-819294	20030616
	JP 2006513695	T	20060427	JP 2004-513326	20030616
	MX 2004012656	A	20050815	MX 2004-12656	20041214
	US 20080050311	A1	20080228	US 2007-849791	20070904
	AU 2008212083	A1	20081002	AU 2008-212083	20080910
PRAI	US 2002-388314P	P	20020614		
	AU 2003-277087	A3	20030616		
	US 2003-461885	A3	20030616		
	WO 2003-GB2593	W	20030616		

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	133.36	133.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.02	-9.02

FILE 'STNGUIDE' ENTERED AT 11:54:03 ON 15 JUN 2009

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 12, 2009 (20090612/UP).

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	134.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.02

STN INTERNATIONAL LOGOFF AT 11:59:33 ON 15 JUN 2009